Immune cell therapy takes on Hard-to-Treat cancers
NCT ID NCT07410676
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose interleukin-15 to support the cells, and some also get the drug pembrolizumab. The goal is to see if this combination is safe and can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
District One Hospital
RECRUITINGBeijing, Beijing Municipality, 086-373, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Could sitting up make radiation therapy more comfortable?
- Can we predict chemo brain before it happens?